Physician profile
Christopher Baldwin
NPI 1033159074
$844.76
in general payments reported to CMS, 2019-2025
13 companies · $23.33 in 2025
The $23.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $416 · 2022: $53.49 · 2023: $352 · 2025: $23.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $448.57 | 2020-2023 | Trelegy Ellipta |
| Abbvie INC. | $79.47 | 2023 | Qulipta, Linzess, Viberzi |
| Lilly USA, LLC | $68.90 | 2022-2023 | Jardiance |
| Mindray Ds USA, INC. | $49.65 | 2023 | Te7 Max, Te X |
| Bayer Healthcare Pharmaceuticals INC. | $35.27 | 2023 | |
| Pfizer INC. | $32.80 | 2023 | |
| Novo Nordisk INC | $23.33 | 2025 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $22.15 | 2022 | |
| Exact Sciences Corporation | $20.08 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.01 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $16.02 | 2023 | Breztri |
| Sanofi-Aventis U.S. LLC | $15.87 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.64 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Baldwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.